| 摘要 |
<p>Disclosed is the use of an anti-Folate receptor 1 (FOLR1) immunoconjugate in the manufacture of a medicament for treating cancer in a subject, wherein increased expression of FOLR1 in a cancer sample from said subject has been detected using a detection method that distinguishes between staining intensity or staining uniformity in a FOLR1 expressing cancer sample as compared to staining intensity or staining uniformity in one or more reference sample, wherein said anti-FOLR1 immunoconjugate has the formula (A)–(L)–(C) or (C)–(L)–(A), wherein: (A) is an anti-FOLR1 antibody or antigen binding fragment thereof comprising: (a) a heavy chain CDR1 comprising GYFMN (SEQ ID NO:6); a heavy chain CDR2 comprising RIHPYDGDTFYNQKFQG (SEQ ID NO:7); and a heavy chain CDR3 comprising YDGSRAMDY (SEQ ID NO:8); and (b) a light chain CDR1 comprising KASQSVSFAGTSLMH (SEQ ID NO:9); a light chain CDR2 comprising RASNLEA (SEQ ID NO:10); and a light chain CDR3 comprising QQSREYPYT (SEQ ID NO:11), (L) is a linker, and (C) is a cytotoxic agent, and wherein the linker (L) links (A) to (C).</p> |
